Skip to Content

RxSight, Inc.

Securities Class Action

  • Date:
  • 7/15/2025
  • Company Name:
  • RxSight, Inc.
  • Stock Symbol:
  • RXST
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ:RXST) on behalf of RxSight stockholders. Our investigation concerns whether RxSight has violated the federal securities laws and/or engaged in other unlawful business practices.

On July 8, 2025, RxSight issued a press release announcing select preliminary financial results for the second quarter of 2025. Among other items, RxSight announced expected revenue of $33.6 million, "representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025." The Company also sharply revised its 2025 revenue guidance, cutting the midpoint from $167.5 million to $125 million. Following RxSight's announcements, Wells Fargo and BTIG both downgraded RxSight, citing "structural issues" and "a continued tough competitive environment."

On this news, RxSight's stock price fell $4.84 per share, or 37.84%, to close at $7.95 per share on July 9, 2025.
If you purchased or otherwise acquired RxSight shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in RxSight. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: